Itraconazole Therapy In Bronchiectasis With Airway Mold

Who May Qualify: - Age ≥18 years seen at Mycobacterial and Bronchiectasis Clinic (MMBC) in Rochester - Diagnosis of bronchiectasis confirmed by MMBC provider and chest CT - Within the last 3 months - culture growth of a mold in high quantity ('many') or culture growth of at least two distinct mold species in any quantity - Not actively on antimicrobial therapy AND no current plan to initiate antimicrobial therapy at the time of enrollment, as determined by treating provider - Ability to produce spontaneous sputum at Visit 1. Who Should NOT Join This Trial: - Known diagnosis of allergic bronchopulmonary aspergillosis or invasive fungal disease - Use of the following medications: rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, dofetilide, quinidine, dronedarone, simvastatin, lovastatin, certain immunosuppressants (tacrolimus, cyclosporine, sirolimus, everolimus) and anticoagulants (rivaroxaban, apixaban, edoxaban, warfarin). - Abnormal baseline liver function tests (ALT, AST, alkaline phosphatase, or bilirubin \> upper limit of normal) - Prolonged QTc interval on baseline ECG (\>460 ms in females or \>450 ms in males) - History of congestive heart failure (black box warning), known cardiomyopathy, or arrhythmias - Pregnancy or lactation - Known hypersensitivity or contraindication to azole antifungal therapy - Prior use of systemic antifungals within the past 3 months Always talk to your doctor about whether this trial is right for you.